Centessa Pharmaceuticals plc

NASDAQ:CNTA

Biotechnology

Healthcare
$40.50 -0.19%

-$0.07 today

Market cap
$6.27B
Beta
1.12
P/E (TTM)
-24.4
EPS (TTM)
-$1.63
52W Low $12.30High $40.26

Volume 0.00M

Average 2.63M

CNTA EBITDA Margin

EBITDA as a percentage of revenue.

Centessa Pharmaceuticals plcNASDAQ: CNTA

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin not reported for Q1 FY2026

What to watch

Whether EBITDA Margin reaches the consensus estimate from 12 analysts of 20.0% for the fiscal year ending Dec 2026, up from -1222.2% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-1222.2%— YoY
LTMMar 2026
—— YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year—+1242.2 pp—
3 years—+1242.2 pp—
5 years+1242.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-1222.2%
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How CNTA compares with its peers on the latest reported figures

  • CNTA's FY2025 EBITDA Margin of -1222.2% is the 5th highest of the 7 companies compared; the peer median is -135.6%.
CNTA Competitors Peer median
EBITDA Margin for CNTA and competitors
Company Period LTM level YoY 3-year change
LEGNLegend Biotech CorporationLTM Sep 20267.3% +27.5 pp+333.4 pp
ZLABZai Lab LimitedLTM Jun 2026-37.5% +8.1 pp+167.8 pp
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026-75.2% +1.0 pp+105.9 pp
AAPGAscentage Pharma Group InternationalFY2025-196.1% -171.8 pp+179.2 pp
CNTACentessa Pharmaceuticals plcFY2025-1222.2% ——
CGONCG Oncology, Inc. Common stockLTM Sep 2026-3791.2% +3149.4 pp+14598.9 pp
XENEXenon Pharmaceuticals Inc.FY2025-4564.7% —-3210.7 pp
APGEApogee Therapeutics, Inc.FY2025— ——
CELCCelcuity Inc.FY2025— ——
DYNDyne Therapeutics, Inc.FY2025— ——
Peer median (excluding CNTA) -135.6%+8.1 pp+173.5 pp

Competitors are the stored peer set for CNTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue006.85M015M
Cost of Revenue00000
Gross Profit006.85M015M
Gross Margin——100.0%—100.0%
Research & Development96.32M155.08M124.41M150.24M172.22M
Selling, General & Admin43.01M55.2M53.73M50.81M50.47M
Operating Expenses374.87M212.26M178.14M201.06M222.69M
Depreciation & Amortization34K131K810K942K921K
EBITDA(139.3M)(209.55M)(165.43M)(221.88M)(183.33M)
EBITDA Margin——-2413.9%—-1222.2%
Operating Income(374.87M)(212.26M)(171.28M)(201.06M)(207.69M)
Operating Margin——-2499.4%—-1384.6%
Interest Income0244K10.48M14.02M20.53M
Interest Expense2.55M7.28M9.91M10.09M11.46M
Other Income / Expenses(6.92M)(4.69M)(4.86M)(31.86M)11.98M
Income Before Tax(381.79M)(216.95M)(176.14M)(232.91M)(195.71M)
Pre-Tax Margin——-2570.3%—-1304.8%
Income Tax Expense114K(747K)(25.06M)2.84M1.82M
Net Income(381.9M)(216.21M)(151.09M)(235.76M)(197.53M)
Net Margin——-2204.7%—-1316.9%
EPS (Basic)(4.24)(2.31)(1.57)(2.06)(1.46)
EPS (Diluted)(4.24)(2.31)(1.57)(2.06)(1.46)
Weighted Avg Shares89.99M93.4M96.18M114.47M135.72M
Weighted Avg Shares (Diluted)89.99M93.4M96.18M114.47M135.72M

Centessa Pharmaceuticals plc

NASDAQ:CNTA

Intrinsic Alpha fair value

Locked

Current Price

$40.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.